The role of the opioid system in decision making and cognitive control: A review

Henk van Steenbergen¹,² · Marie Eikemo³,⁴ · Siri Leknes⁴

Published online: 8 April 2019
© The Author(s) 2019

Abstract
The opioid system regulates affective processing, including pain, pleasure, and reward. Restricting the role of this system to hedonic modulation may be an underestimation, however. Opioid receptors are distributed widely in the human brain, including the more “cognitive” regions in the frontal and parietal lobes. Nonhuman animal research points to opioid modulation of cognitive and decision-making processes. We review emerging evidence on whether acute opioid drug modulation in healthy humans can influence cognitive function, such as how we choose between actions of different values and how we control our behavior in the face of distracting information. Specifically, we review studies employing opioid agonists or antagonists together with experimental paradigms of reward-based decision making, impulsivity, executive functioning, attention, inhibition, and effort. Although this field is still in its infancy, the emerging picture suggests that the mu-opioid system can influence higher-level cognitive function via modulation of valuation, motivation, and control circuits dense in mu-opioid receptors, including orbitofrontal cortex, basal ganglia, amygdalae, anterior cingulate cortex, and prefrontal cortex. The framework that we put forward proposes that opioids influence decision making and cognitive control by increasing the subjective value of reward and reducing aversive arousal. We highlight potential mechanisms that might underlie the effects of mu-opioid signaling on decision making and cognitive control and provide directions for future research.

Keywords Opioid system · Cognitive control · Decision making · Executive function · Value-based choice · Reward · Drugs · Mu-opioid receptors · Affect · Mood · Morphine · Hedonic states

Introduction
Pleasure and pain are powerful motivators that determine a great deal of our behavior in daily life. Opioid drugs are known to dampen pain and increase pleasure (Kringelbach & Berridge, 2009; Leknes & Tracey, 2008). The subjective reports of people taking opioids for pain relief or recreation (De Quincey, 2000) have been corroborated by findings that rodents will work to obtain an opioid but also to avoid opioid blockade (Mucha & Iversen, 1984). Accordingly, many influential theories describe the opioid system as the brain’s regulator of affective states (Barbano & Cador, 2007; Berridge & Kringelbach, 2015; Koob & Le Moal, 2001).

Opioid drugs are the “gold standard” treatment for perioperative pain, for example. These drugs also dampen other aversive experiences, such as the sensation of breathlessness (Hayen et al., 2017), psychosocial stress (Bershad, Jaffe, Childs, & de Wit, 2015; Bershad, Miller, Norman, & de Wit, 2018), and depressive symptoms (Peciña et al., 2018). Evidence from nonhuman animal studies highlights the importance of the opioid system in regulating not just aversive experiences but also motivation and “liking” of food (Baldo, 2016; S. Peciña & Smith, 2010), social contact (Loseth, Ellingsen, & Leknes, 2014), and other rewards (Laurent, Morse, & Balleine, 2015). The available human literature is still limited but is suggestive of a similar hedonic regulation by the human opioid system. A recent review of positron
emission tomography (PET) studies with opioid receptor-specific tracers posit a central role of the opioid system for positive affective states (Nummenmaa & Tuominen, 2017). Drug studies in both human and nonhuman animals show that blocking opioids reduces food pleasantness and consumption, especially for high-calorie foods (Drewnowski, Krahn, Demitrack, Nairn, & Gosnell, 1992; Eikemo et al., 2016; Price, Christou, Backman, Stone, & Schweinhardt, 2016; Yeomans, 1995; Yeomans & Gray, 2002).

For aversive stimuli, blocking opioid signaling can enhance or maintain responses in aversive learning tasks (Eippert, Bingel, Schoell, Yacubian, & Büchel, 2008; Haaker, Yi, Petrovic, & Olsson, 2017). Opioid blockade can also increase the aversiveness of pain (Anderson, Sheth, Bencherif, Frost, & Campbell, 2002), although this effect is rarely observed with short-lasting experimental pain stimuli (Berna et al., 2018; Eippert et al., 2008; Grevert & Goldstein, 1977). Very recently, studies indicate that social reward processes are similarly modulated by opioids in humans. Indeed, opioid agonist and/or antagonist drugs have been reported to modulate the perceived attractiveness and motivation to view faces of beautiful women (Chelnokova et al., 2014), the relative pleasantness of nude images and frustration at missed opportunity to view these (Buchel, Miedl, & Sprenger, 2018), visual exploration of faces (Chelnokova et al., 2016), and perception of faces with emotional expressions (Bershad, Seiden, & de Wit, 2016; Loseth et al., 2018; Syal et al., 2015; Wardle, Bershad, & de Wit, 2016).

Overall, these findings are in line with the notion that mu-opioid receptor stimulation by endogenous and exogenous opioid peptides causes a shift in valuation along a “hedonic gradient,” ranging from displeasure to pleasure. This shift is not limited to the “liking” of stimuli. Learning and motivation typically increase with increased valuation (Berridge, Robinson, & Aldridge, 2009). Evidence from nonhuman animal studies also shows opioid modulation of learning independently of “liking” responses (Laurent et al., 2015). Moreover, microstimulation with opioid peptides has been shown directly to increase motivation for different reward types in rodents (Mahler & Berridge, 2012) through distinct neural mechanisms (Wassum, Ostlund, Maidment, & Balleine, 2009a).

In rodents, wanting, liking, and reward learning can be modulated by manipulations of opioid receptors in the ventral and dorsal striatum, ventral pallidum, and the central nucleus and basolateral parts of the amygdala (Berridge & Kringelbach, 2015; Wassum, Cely, Balleine, & Maidment, 2011; Wassum, Cely, Maidment, & Balleine, 2009b; Wassum, Ostlund, et al., 2009a). Recently, “hedonic hot-and coldspots” involved in sweet taste “liking” responses also were identified in the rat insula and prefrontal cortices (Castro & Berridge, 2017). Studies using PET imaging and pharmacological MRI in humans suggest that opioids may indeed exert their effects on reward-related behavior through receptors in the orbitofrontal cortex, amygdala, thalamus, insular cortices, ventral and dorsal striatum, and cingulate cortices (Hsu et al., 2013; Love, Stohler, & Zubieta, 2009; Murray et al., 2014; Nummenmaa et al., 2018; Petrovic et al., 2008; Rabiner et al., 2011). A large meta-analysis of fMRI activation associated with subjective value processes showed that the striatum and ventro-medial prefrontal areas (including the orbitofrontal cortex) are key to the valuation process, whereas a different network comprised of the anterior insula, dorsomedial prefrontal cortex, dorsal and posterior striatum, and thalamus may be recruited in response to arousal or salience during valuation (Bartra, McGuire, & Kable, 2013).

Recently, rodent researchers have argued convincingly for opioid involvement in choice behaviors beyond the regulation of reinforcement and aversion (Laurent et al., 2015). Indeed, the widespread distribution of opioid receptors throughout the human brain is consistent with a wider role of this neuromodulator for cognition and behavior (Figures 1 and 2). Opioid activation and inhibition also affects other neurotransmitter systems important for cognition, such as dopamine and norepinephrine (Chajjale et al., 2013; Fields & Margolis, 2015; Valentino & Van Bockstaele, 2015).

**Opioid regulation of cognitive control and decision making?**

By altering motivational processing and/or learning, opioid drugs could exert profound effects on cognitive control and reward-based decisions even after a single drug administration. Work in rodents indeed shows opioid-induced impairments in some measures of sustained attention and response inhibition (for an up-to-date review see, Jacobson, Wulf, Browne, & Lucki, 2018). Despite decades of nonhuman animal research, much less is known about acute opioid modulation of cognition and decision making in humans. Although a general assumption has been that opioid drugs will impair concentration, human drug studies collecting measures of cognitive control and executive function have typically lacked a strong theoretical motivation for task inclusion.

One recurrent idea in the human literature is that opioids might impair concentration by reducing arousal and discomfort, whereas this same arousal-reducing property might improve cognitive function when participants are tested in stressful situations (Evans & Witt, 1966). Research from the past decade has renewed interest in how arousal can influence cognitive control (Aston-Jones & Cohen, 2005). Some studies have highlighted the specific effects of aversive arousal, i.e., heightened arousal in combination with negative valence (Saunders & Inzlicht, 2015; van Steenbergen, 2015). In models that describe affect as a two-dimensional space with the factors arousal and valence (Russell, 2003), aversive...
arousal can be conceptualized as a diagonal in the quadrant that combines high levels of arousal with negative valence (Thayer, 1989; Yik, Russell, & Barrett, 1999). Aversive arousal is an integral affective response in many tasks requiring cognitive control (Inzlicht, Bartholow, & Hirsh, 2015). Recent accounts have suggested that aversive arousal tunes goal-directed behavior (Dreisbach & Fischer, 2015; van Steenbergen, Band, & Hommel, 2009) and can be counteracted by the induction of incidental positive affect (van Steenbergen, 2015). Accordingly, it is conceivable that positive affect induced by an opioid drug might downregulate aversive arousal, thereby influencing cognitive control. Such opioid effects would be consistent with emerging work on the stress-relieving properties of opioids (Valentino & Van Bockstaele, 2015).

In the present paper, we present a synthesis of current knowledge of opioid regulation of decision making and the control of goal-directed behavior in the healthy human brain. The studies reviewed have used pharmacological manipulations in healthy humans together with decision-making and cognitive-control tasks. Where possible, we also draw on relevant evidence from PET imaging. Our primary objective is to gain a better understanding of the mechanisms of acute opioid modulation of cognitive processes. We also discuss the

**Fig. 1** Neural circuits involved in decision making (A) and cognitive control (B) based on meta-analyses (analysis date 24 May 2018), showing forward inference maps of statistically significant (false discovery rate, \( p < 0.01 \)) activations in Neurosynth (Yarkoni, Poldrack, Nichols, Van Essen, & Wager, 2011). (C) Density of mu-opioid receptor expression as revealed by [11C]-carfentanil PET (mean nondisplaceable binding potential (BPND) image of 89 PET scans from healthy volunteers; courtesy of Dr. Lauri Nummenmaa). The circuits involved in decision making and cognitive control show particular high density of mu-opioid receptors in the limbic system (including thalamus, basal ganglia, and cingulate cortex) and a moderate density of mu-opioid receptors in cortical regions, such as insular and lateral-prefrontal cortex. Note that mu-opioid receptors regulate many functions. As shown above, receptors are expressed throughout the brain, including in regions less commonly associated with cognition, such as the midbrain (periaqueductal gray), hypothalamus, and cerebellum. These maps and their conjunctions are available at Neurovault (Gorgolewski et al., 2015): https://neurovault.org/collections/4841/
possible role of the mu-opioid system in indirect modulation of decision-making and cognitive control via changes in affective states (Braver et al., 2014; Chiew & Braver, 2011; Dreisbach & Goschke, 2004; Isen & Means, 1983; Notebaert & Braem, 2016; van Steenbergen, 2015; Vinckier, Rigoux, Oudiette, & Pessiglione, 2018) and stress (Shields, Janecka, Costentin, & Do Rego, 2007). Drugs, such as morphine and heroin, are considered mu-opioid agonists, i.e., they act primarily on the mu-opioid receptor (Pasternak, 2001). The drugs that block endogenous opioid signaling (agonists, such as naloxone or naltrexone) in humans typically inhibit activity at both mu- and kappa-receptors. To date, the mechanism of action of the mu-opioid receptor is best understood. Both the analgesic and the euphoric effects of opioid drugs are thought to be mediated by this receptor type (Fields & Margolis, 2015). Although mu-opioid receptors are widely distributed in the brain (and in other parts of the body as well), they are in particular highly expressed in limbic brain areas, such as the basal ganglia, thalamus, and anterior cingulate. They also are expressed to a moderate extent in cortical areas, such as lateral prefrontal and insular regions (Henriksen & Willoch, 2008). Right panel: Mu-opioid receptors are activated by a large number of different drugs, and they are commonly compared in terms of their efficacy to relieve pain at a particular dose and administration method. Opioid drugs are often given as pills (per oral; PO) but also intravenously (IV), transnasally (TN), subcutaneously (SC), and intramuscularly (IM). We have calculated a rough estimate of “morphine equivalence” on the basis of available evidence of analgesic effects. This conversion was primarily based on the values provided in earlier work (Knotkova, Fine, & Portenoy, 2009; Zacny, 1995). It is important to emphasize that dosages with similar analgesic properties can have different effects on cognitive function, and a simple conversion does not capture the different pharmacokinetics of different drugs. To emphasize that the conversion is coarse for the present purposes, we do not report the exact equianalgesic doses of morphine. Instead, we have categorized the dose as a low, medium, or high dose, using 4 mg and 7 mg IV of morphine as the minimal cutoff values for the medium and high dose, respectively. As for the opioid antagonists, these were categorized on the basis of available PET evidence about the proportion of mu-opioid receptors blocked by a given drug dose (Mayberg & Frost, 1990). Doses covering 90-100% of receptors are considered full antagonists (Weerts et al., 2013). Where doses administered were much higher or lower than this range, this is specified in the text. In addition to drugs acting primarily as agonists or antagonist to opioid receptors, the literature also contains several reports from “mixed agonists,” i.e., drugs that act simultaneously as agonists and antagonists at different opioid receptors (Jacob, Michaud, & Tremblay, 1979). This category also covers drugs that act as partial agonists and antagonists, such as buprenorphine, which binds strongly to mu-opioid receptors, but causes less activation of the receptor than the endogenous ligand. Buprenorphine is also a kappa-opioid antagonist. These drugs were also categorized on the basis of their analgesic effects at the doses used in the literature. Figures were produced with graphics from Servier Medical Art (smart.servier.com) under Creative Commons BY 3.0 license.

**Literature inclusion**

To synthesize the available evidence for acute opioid drug effects on cognition in healthy human volunteers, we searched for studies combining opioid agonist and antagonist drugs with experimental paradigms to investigate decision making, impulsivity, executive functioning, attention, inhibition, and effort. We used Pubmed, Scopus and Google Scholar to search for relevant literature, using a combination of the keyword “opioid” or drug names, such as naltrexone, naloxone, remifentanil, buprenorphine, oxycodone, and morphine and the particular cognitive function (e.g., attention, impulsivity, decision-making). In addition, we included relevant articles cited in recent papers or in earlier reviews by Zacny (1995) and Ersek et al. (2004). Studies were included in this semisystematic review if they were published as an article in a peer-reviewed scientific journal, had tested healthy human volunteers, included a pharmacological manipulation with an
opioid agonist and/or antagonist drug, and included one or more paradigms related to the domains of decision making or cognitive control. Both behavioral results and/or neural effects using EEG or fMRI were included in the review. For reasons of clarity and feasibility, papers published before 1957 and studies that measured the relevant drug effects during pain or in combination with another drug were not considered. Beyond these limitations, we strive to include all relevant studies rather than reviewing a subset. Accordingly, we consider our approach a semisystematic review, in the sense that we did not knowingly exclude evidence contrary to (or consistent with) our own opinions about the topic at hand. To compare the different drugs and their doses, we calculated a rough estimate of “morphine equivalence” on the basis of available evidence of analgesic effects (Figure 2).

A quantitative meta-analysis of effects in the reviewed literature was not possible due to 1) variable drug types, doses, and administration methods used across studies, 2) variable tasks and outcome measures reported, and 3) the failure to report means and variance information for relevant outcomes in much of the (earlier) literature. Note that this literature has typically been statistically underpowered, and for topics where both null and positive effects are reported, we give relatively less weight to null findings identified using frequentist statistics only.

**Review of studies on decision-making**

**Reward-based decision-making**

Only a handful of studies have investigated the behavioral, neural, and psychophysiological responses to reward-based decisions following pharmacological manipulation of the opioid system in healthy humans. In general, these studies are consistent with the available evidence on opioid modulation of rewards presented outside of a decision context. Petrovic and colleagues (Petrovic et al., 2008) used opioid blockade (10 mg IV naloxone, placebo-controlled) to assess the role of endogenous opioids during a gambling task with rewards and losses in 15 healthy men (within-subject). Following naloxone, monetary losses were rated as more aversive and the opioid blockade increased activation in regions such as the ACC and anterior insula. Pleasantness ratings of wins were unaltered by opioid blockade, which nevertheless decreased ACC responses to these rewards. Another study reported no clear effects of opioid blockade (50 mg naltrexone) on BOLD responses to monetary wins and losses (Monetary Incentive Delay task) in 35 healthy participants (Nestor et al., 2017). Very recently, a third fMRI study using naloxone and an incentive delay task with monetary gain and erotic images in 21 healthy men (within-subject) found that compared with placebo, opioid blockade decreased the relative pleasantness of both types of high-value rewards but with a significantly stronger effect on erotic images (Buchel et al., 2018). The authors observed reduced BOLD response to erotic images in bilateral striatum, orbitofrontal cortex, the amygdala, prefrontal cortex, and hypothalamus but no reduced response to (symbolic) receipt of monetary gains. During the anticipation phase, a small reduction in medial prefrontal cortex and right lateral orbitofrontal cortex activity was observed during cues signaling potential monetary gains (but not erotic images).

Thus, initial evidence of opioid modulation of pleasantness and fMRI responses to rewarded decisions in humans is modest but consistent with the evidence that opioids promote the pleasantness of rewards received outside of a decision context (Chelnokova et al., 2014; 2016; Drewnowski et al., 1992; Eikemo et al., 2016; Murray et al., 2014; Price et al., 2016; Yeomans, 1995; Yeomans & Gray, 2002). Whether opioid agonist drugs increase the liking of choice outcomes in humans remains to be seen.

**Reward learning and motivation in decision making**

What about opioid modulation of reward learning and motivation in humans? Studies using measures of motivation and learning have shown more consistent opioid modulations than those on reward responses. Using a Pavlovian instrumental transfer (PIT) task with chocolate reinforcement, Weber et al. (2016) found a significant reduction in the difference between button presses for rewarded and unrewarded stimuli following 50 mg naltrexone (n = 40) compared with placebo (n = 40), indicating reduced motivation to exert effort for rewards after opioid blockade. Eikemo et al. (2017) tested the effects of 50 mg of naltrexone, 10 mg of morphine, and placebo on rewarded choice in healthy men (n = 30, within-subjects). Using a drift diffusion model, they found that mu-opioid agonism enhanced and blockade decreased, processing efficiency in the reward task, which they interpreted as a measure of motivation to obtain reward. Morphine also increased the bias towards the high-value response option (associated with high reward probability). Using opioid blockade (50 mg of naltrexone, n = 21) and placebo (n = 20) before a slot-machine task and roulette task, Porchet et al. (2013) found that naltrexone moderately attenuated the motivational ratings after near-misses compared with placebo. However, contrary to the above reviewed findings, participants under opioid blockade also exhibited signs of increased reward sensitivity (a larger change in the skin conductance response to wins and higher confidence following winning-streaks). Finally, a study of opioid effects on financial decisions (trading game) suggested that opioid blockade (naltrexone 50 mg, n = 62) decreases reinforcement learning compared with placebo (n = 116) in healthy participants (Efremidze, Sarraf, Miotto, & Zak, 2017).
In summary, the available evidence provides some support for involvement of the endogenous opioid system in value-based decision making, suggesting that blocking opioid receptors may reduce, and stimulating receptors may enhance, the motivational value of and learning about high-value stimuli and choices for these options. However, pharmacological studies in healthy humans are still scarce, and results are not homogenous. So far, the opioid effects on value-based decision making appear broadly consistent with the extensive evidence from rodent research (Berridge & Kringelbach, 2015; Laurent et al., 2015; Lutz & Kieffer, 2013), but more research into this area in humans is needed.

**Impulsive choices**

Impulsivity is a broad construct related to impulsive choice (as measured by probability discounting, gambling tasks, and delay discounting) and impulsive action (e.g., failure to inhibit prepotent responses, see Inhibition and Effort). Correlations between trait impulsivity and performance on tasks measuring impulsive choice or action are low, as are correlations of performance between these tasks. Nevertheless, trait impulsivity has been related to opioid receptor binding in a PET study. Specifically, NEO Personality Inventory (Costa & McCrae, 1992) measures related to lack of control over cravings or desires, correlated with receptor-binding potential in medial frontal cortex, nucleus accumbens/ventral pallidum, and the right amygdala in 19 young males (Love et al., 2009).

A handful of opioid drug studies have investigated impulsive choices using delay discounting tasks where subjects choose between smaller immediate rewards or larger delayed rewards. Two initial studies reported no significant effect of naltrexone (50 mg PO) on impulsive choice ratio in nine (Mitchell, Tavares, Fields, D’Esposito, & Boettiger, 2007) and ten healthy controls (Boettiger, Kelley, Mitchell, D’Esposito, & Fields, 2009). In a larger study by Weber et al. (2016), a trend towards reduced impulsive choice was reported in 40 healthy people receiving naltrexone (50 mg) compared with a placebo group of the same size. Few studies report effects of opioid agonism on impulsivity measures in healthy humans. In Zacny and de Wit (2009), a battery of five tasks measuring aspects of choice and motor impulsivity was administered following three separate doses of oxycodone (5, 10, or 20 mg PO) compared with placebo (within-subject; n = 12). They did not find any significant effect on any of the tasks, including delay discounting, even at the higher oxycodone doses where participants reported feeling the drug effects. Furthermore, Eikemo et al. (2017) found no credible effects of either 50 mg of naltrexone or 10 mg of morphine on reward-related impulsivity as measured by speed-accuracy trade-off in a probabilistic reward task.

Together, these results indicate that blocking the majority (>90%) of the μ-opioid receptors in the brain using 50 mg of naltrexone (Weerts et al., 2013) does not cause a large reduction in measures of impulsive reward choices in healthy humans. Rodent work similarly indicates limited or no effects of opioid blockade on tests of impulsive behavior (Kieres et al., 2004; Pattij, Schetters, Janssen, Wiskerke, & Schoffelmeer, 2009). For opioid agonism, the preliminary evidence in humans is at odds with rodent findings that acute opioid administration increases impulsivity.

### Review of studies on cognitive control

#### Neuropsychological tests of executive functions

The nonhuman animal literature yields minimal information about opioid modulation of executive function. These functions are typically impaired in opioid dependence, but this impairment could be related to other factors and mechanisms than opioid receptor functioning. Indeed, working memory training was shown to increase future orientation and decrease delay discounting in opioid-dependent individuals (Bickel, Yi, Landes, Hill, & Baxter, 2011). While the little evidence available from opioid antagonist studies do not suggest a central role of the endogenous opioid system in executive function, studies employing acute doses of opioid agonists do report modulation of executive functions.

Most consistent evidence for an impact of opioid drugs on executive function comes from studies implementing the digit symbol substitution task (DSST, also known as the coding task), which requires participants to substitute symbols and digits using a particular key. The DSST is the most commonly included task in opioid administration studies. A speeded subtest of the Wechsler Adult Intelligence Scale, it is designed to measure functions related to “processing speed” (Wechsler, 2014). However, recent work has shown that the DSST task does not assess basic psychomotor speed, but instead reflects a mixture of executive functioning processes including inhibition, shifting, and updating (Knowles et al., 2015).

An early study reported that a low dose of the opioid agonist codeine impairs coding performance in medical troops tested at 2,000 feet (610 meters) altitude but improved performance when they performed this test at 15,000 feet (4,572 meters) elevation (Evans & Witt, 1966). Few subsequent studies have assessed context-sensitive effects of opioids on cognition. Instead most studies have simply included DSST performance as part of a cognitive test battery in a standard psychopharmacological protocol with no systematic manipulation of context. More than 30 such studies have investigated the effects of various types of opioid agonists. The majority of these studies have observed coding impairments (Table 1). Two studies using opioid antagonists reported no effect on coding performance (File & Silverstone, 1981; Zacny, Coalson, Lichtor, Yajnik, & Thapar, 1994a). As Figure 3 (left)
panel) shows, most performance impairments have been reported in studies using high doses of opioid agonists only, although some studies have observed performance decrements at medium doses (e.g., hydrocodone, oxycodone, and partial agonists). This suggests that the effect of opioid agonists on coding performance might be dose-related, even though a clear link between plasma concentrations and DSST impairments is currently lacking (Strand, Arnestad, Fjeld, & Mørland, 2017).

Another commonly investigated function in the context of opioid drugs is logical reasoning. Effects of opioid agonists on a logical reasoning task were first reported by Evans and Smith (1964) who observed that a low dose of morphine in four participants improved performance on a test assessing logical judgements compared with four placebo-treated people. However, the majority of subsequent studies in larger samples have failed to replicate this effect with low opioid drug doses (Table 2), although some impairments in logical reasoning have been observed with medium and high doses of full and mixed agonists (Figure 3, right panel). We are not aware of studies that have reported the effects of opioid antagonists on logical reasoning.

Working memory is a central aspect of executive functioning that is well known to be modulated by catecholamine systems that directly modulate prefrontal brain activity (Robbins & Arnsten, 2009). Interestingly, across a wide variety of doses and drugs in 16 studies, opioid agonists and antagonists typically do not affect working memory performance (Table 3). Three studies did observe effects on working memory (Ghoneim, Mewaldt, & Thatcher, 1975; Martín del Campo, McMurray, Besser, & Grossman, 1992; Székely, Török, Karczag, Tolna, & Till, 1986) but showed findings in opposite directions and had small study samples (8 or 10 males per study).

The handful of studies assessing effects of opioid agonist and antagonist treatment on mathematical skills are summarized in Table 4. The available evidence suggests that high doses of opioids drugs might impair several aspects of mathematical skills, including the speed at which participants complete oral and written addition tasks as reported by Smith and colleagues (Smith, Semke, & Beecher, 1962). However, other studies using low or moderate doses of opioid agonists failed to observe effects (Cleeland et al., 1996; Kornetsky, Humphries, & Everts, 1957; Cherrier, Amory, Ersek, Risler, & Shen, 2009). Opioid blockade has not been shown to modulate arithmetic skills (Martín del Campo et al., 1992).

Cognitive flexibility, another key aspect of executive function, is rarely investigated in the context of opioid drug studies. In an early study, Primac et al. (1957) did not find an effect of a low dose of the opioid agonist Meperidine administered to ten participants on the Wisconsin Card Sorting Test (WCST). More recently, Quednow and colleagues (Quednow, Csomor, Chmiel, Beck, & Vollenweider, 2008) using a low dose of 10 mg PO of morphine in 18 males did not observe effects on the Stockings of Cambridge tasks or extradimensional set shifting. However, their low dose of morphine did reduce the error rate on intradimensional set shifts, suggesting that low doses of opioids might help to improve the application of a task rule within the same perceptual dimension.

The effects of opioid drugs on neuropsychological tests of executive function have most often been investigated in the domains of coding, logical reasoning, and working memory. While a large proportion of studies did observe opioid agonist-induced impairments in coding and logical reasoning, there are no consistent effects of opioid drugs on working memory.

### Attention

In an early study, Arnsten et al. (1983, 1984) hypothesized that blocking endogenous opioid activity might improve the selectivity of attention. Using a small dose (2 mg IV) of naloxone in an EEG study of ten male participants, they indeed observed that naloxone increased a late frontal event-related potential component, which is thought to reflect attention to auditory stimuli. Findings were consistent with their prior findings in animals (Arnsten et al., 1981) and were suggested to be driven by interactions with the locus-coeruleus-norepinephrine system. However, a more recent study testing four females and nine males using a higher dose of the opioid antagonist naltrexone (50 mg PO) to block >90% of mu-opioid receptors observed an effect in a direction opposite to the findings by Arnsten and colleagues (Jääskeläinen et al., 1998). These authors speculated that the observed impairment in selectivity of attention in their study might be due to nausea induced by naltrexone in their participants. Thus, a full opioid blockade (>90%) appears to cause the opposite attentional effect of weak opioid blockade. Other studies using high doses of opioid agonists did not observe clear impairments in divided attention task performance (Saarialho-Kere, 1988; Saarialho-Kere, Mattila, & Seppälä, 1989; for procedural details of these studies see Table 1). These null-effects were supported by the finding that a low dose of infused remifentanil (n = 14, within-subjects) impaired attention in a letter detection task only when participants expected that the drug would be administered but not when they did not expect the drug (open vs. hidden administration; Atlas, Wielgosz, Whittington, & Wager, 2014).

The ability to regulate sensory input by filtering out irrelevant stimuli (to prevent sensory overflow) can also be enhanced by opioid agonists, as suggested by a study where a low dose of morphine (10 mg PO) in 18 males enhanced modulation of the startle reflex to a noise burst following a prestimulus, a phenomenon called prepulse inhibition (Quednow et al., 2008). At first sight, these findings seem difficult to reconcile with the findings reported by Arnsten et al. (1983, 1984). As we will discuss in more detail later,
| Reference                                      | Sample    | Drug type | Drug    | Route | Dose    | Max dose | Effect1 | Effect2 | Effect3 |
|-----------------------------------------------|-----------|-----------|---------|-------|---------|----------|---------|---------|---------|
| Kornetsky, Humphries, & Evarts, 1957          | 4F/6M     | Agonist   | Meperidine | PO    | 50, 100 mg | low      | ...     | ...     | ...     |
| Smith, Serke, & Beecher, 1962 (Study 1)      | 24M       | Agonist   | Morphine  | SC    | 10 mg   | high     | ↓       | high    | ↓       |
| Smith, Serke, & Beecher, 1962 (Study 2)      | 24M       | Agonist   | Heroin    | SC    | 4 mg    | high     | ↓       | high    | ↓       |
| Evans & Wit, 1966                            | 16M       | Agonist   | Morphine  | PO    | 32 mg   | high     | ↓       | high    | ↓       |
| File & Silverstone, 1981                     | 6F/6M     | Antagonist| Naloxone  | IV    | 0.8, 1.6 mg | -low     | ...     | ...     | ...     |
| Jarvik, Simpson, Guthrie, & Liston, 1981     | 20M       | Agonist   | Morphine  | IM    | 10 mg   | high     | ↓       | high    | ↓       |
| Redpath & Pleuvry, 1982                      | 4F/6M     | Agonist   | Codeine   | PO    | 30, 60 mg | low      | ↓       | high    | ↓       |
| Bradley & Nicholson, 1986                    | 6F        | Agonist   | Codeine   | PO    | 30, 90 mg | med      | ↓       | high    | ↓       |
| Saarialho-Kere, Mattila, & Seppälä, 1986     | 10F/M     | Agonist   | Codeine   | PO    | 100 mg   | med      | ↓       | high    | ↓       |
| Saarialho-Kere, Mattila, & Seppälä, 1987     | 7F        | Mixed     | Pentaizol | PO    | 100, 200 mg | high     | ↓       | high    | ↓       |
| Saarialho-Kere, Mattila, & Peelope, 1988     | 12F/M     | Mixed     | Pentaizol | PO    | 0, 25, 50 mg | low      | ↓       | high    | ↓       |
| Saarialho-Kere, Mattila, & Seppälä, 1988     | 5F/7M     | Mixed     | Nalbuphine| IM    | 0-10.5 mg | high     | ↓       | high    | ↓       |
| Saarialho-Kere, Mattila, & Seppälä, 1989     | 11F/M     | Mixed     | Pentaizol | IM    | 30 mg   | med      | ↓       | med     | ↓       |
| MacDonald, Gough, Nicoll, & Dow, 1989         | 12M       | Mixed     | Buprenorphine | IM   | 0.3 mg | high     | ↓       | high    | ↓       |
| Saarialho-Kere, Mattila, & Seppälä, 1989     | 9F/M      | Agonist   | Oxycodone | IM    | 9.1 mg   | high     | ↓       | high    | ↓       |
| Zacny, Lichtor, & de Wit, 1992               | 6M        | Agonist   | Fentanyl  | IV    | 0.050 mg | med      | ↓       | med     | ↓       |
| Zacny et al., 1993                           | 1F/9M     | Agonist   | Morphine  | IV    | 17.5-70 mg | high     | ↓       | high    | ↓       |
| Oliveto, Bickel, Kamien, Hughes, & Higgins, 1994 | 2F/7M   | Agonist   | Hydromorphone | PO  | 1-6 mg | high     | ↓       | high    | ↓       |
| Veselin et al., 1994                         | 1F/2M versus 3F/3M | Agonist      | Fentanyl | IV    | Continuous infusion: 1, 1.5, 2.5 ng/ml | high     | ↓       | med     | ↓       |
| Zacny, Conley, L. J., & Thapar, 1994c (Study 1) | 3F/6M     | Antagonist| Naloxone  | IV    | 0, 0.01, 0.1, 1.0 mg | -low     | ...     | ...     | ...     |
| Zacny, Conley, L. J., & Thapar, 1994a (Study 2) | 3F/5M     | Antagonist| Naloxone  | IV    | 0, 1, 3, 10 mg | -med     | ...     | ...     | ...     |
| Zacny, Lichtor, Flemming, & Coleson, 1994b   | 2F/10M    | Agonist   | Morphine  | IV    | 2.5-10 mg | high     | ↓       | high    | ↓       |
| Zacny, Lichtor, Thapar, et al., 1994c         | 5F/7M     | Agonist   | Morphine  | IV    | 10 mg   | high     | ↓       | med     | ↓       |
| Zacny, Lichtor, Klafta, Ness, & Axelsen, 1996 | 3F/7M     | Agonist   | Codeine   | PO    | 60 mg Codeine/600 mg Acetaminophen | low      | ...     | ...     | ...     |
| Zacny, Conley, & Galinkin, 1997a             | 5F/11M    | Agonist   | Morphine  | IV    | 10 mg   | high     | ↓       | med     | ↓       |
| Zacny, Conley, & Marks, 1997b                | 4F/12M    | Agonist   | Morphine  | IV    | 2.5, 5, 10 mg | high     | ↓       | high    | ↓       |
| Walker & Zacny, 1998                         | 3F/9M     | Agonist   | Codeine   | PO    | 60, 120 mg | high     | ↓       | high    | ↓       |
| Zacny, Hill, Black, & Sadeghi, 1998          | 15F/2M    | Agonist   | Hydromorphone | IV  | 33, 65, 1.3 mg | high     | ↓       | high    | ↓       |
| Black, Hill, & Zacny, 1999                   | 2F/8M     | Agonist   | Alfentanil | IV    | 16, 32, 64 ng/ml | high     | ↓       | high    | ↓       |
Table 1 (continued)

| Reference                  | Sample  | Drug type | Drug          | Route | Dose                      | Max dose1 | Effect2 | Effect dose3 |
|----------------------------|---------|-----------|---------------|-------|---------------------------|-----------|---------|--------------|
| Walker & Zacny, 1999       | 6F/10M  | Agonist   | Remifentanil  | IV    | Continuous infusion: 0.75, 1.5, 3 ng/ml | high      | ↓       | med          |
| Agonist                    |         | Hydromorphone | IV | Cumulative injections of: 33, 65, 1.3 mg | high      | ↓       | high         |
| Agonist                    |         | Meperidine | IV | Cumulative injections of: 17.5, 35, 70 mg | high      | ↓       | high         |
| Agonist                    |         | Morphine  | IV | Cumulative injections of: 2.5, 5, 10 mg | high      | ↓       | high         |
| Hill & Zacny, 2000         | 5F/12M  | Agonist   | Hydromorphone | IV    | Cumulative injections of: 33, 65, 1.3 mg | high      | ↓       | high         |
| Agonist                    |         | Morphine  | IV | Cumulative injections of: 5, 10 mg | high      | ↓       | high         |
| Marsch et al., 2001        | 18M     | Agonist   | Morphine      | IV    | Three infusion rates (2 min bolus, 15 min, and 60 min) of: 5, 10 mg | high      | ↓       | high         |
| Walker, Zacny, Galva, & Lichtor, 2001 | 5F/10M  | Agonist   | Morphine      | IV    | 2.5, 5, 10 mg | high      | ↓       | high         |
| Mixed                      |         | Butorphanol | IV | Cumulative injections of: 0.5, 1, 2 mg | med       | ↓       | med          |
| Mixed                      |         | Nalbuphine | IV | Cumulative injections of: 2.5, 5, 10 mg | high      | ↓       | high         |
| Mixed                      |         | Pentazocine | IV | 7.5, 15 mg | low      | ↓       | high         |
| Zacny & Gutierrez, 2003    | 9F/9M   | Agonist   | Morphine      | PO    | 40 mg | med       | ↓       |
| Zacny, 2003                | 9F/9M   | Agonist   | Oxycodone     | PO    | 5 mg Hydrocodone/1.5 mg Homatropine, 10 mg Hydrocodone/3 mg Homatropine, 20 mg Hydrocodone/6 mg Homatropine | med      | ↓       | med          |
| Zacny & Goldman, 2004      | 9F/9M   | Agonist   | Morphine      | PO    | 40 mg | med       | ↓       |
| Zacny & Gutierrez, 2008    | 8F/8M   | Agonist   | Hydrocodone   | PO    | 5 mg Hydrocodone/325 mg Acetaminophen, 10 mg Hydrocodone/650 mg Acetaminophen | med      | ↓       |
| Zacny & Lichtor, 2008      | 10F/10M | Agonist   | Morphine      | PO    | 30, 60 mg | high      | ↓       |
| Cherrier, Amory, Ensey, Risler, & Shen, 2009 | 40F/31M | Agonist   | Oxycodone     | PO    | 10, 20 mg | high      | ↓       |
| Zacny & Gutierrez, 2009    | 10F/10M | Agonist   | Hydrocodone   | PO    | 15 mg Hydrocodone/487 mg Acetaminophen, 30 mg Hydrocodone/975 mg Acetaminophen | high      | ↓       |
| Zacny & Gutierrez, 2011    | 6F/8M   | Agonist   | Oxycodone     | PO    | 10 mg | med       | ↓       |

F = female; M = male participants. Studies used within-subject designs unless otherwise noted.

1 Estimated dose for agonists based on morphine equivalent of the maximum dose of in the respective study. For antagonist drugs, the estimated dose is preceded by a minus. See caption of Figure 2 for more details.

2 Arrow indicates significantly improved (↑), impaired (↓), mixed effects (↕) or null-effects (…) on performance relative to a placebo control condition.

3 Minimum estimated dose at which the indicated effect is significantly different from placebo.
one possibility is that the task by Quednow et al. (2008) involved increased levels of distress because of the loud auditory noise involved in the task. Opioids might help to downregulate stress responses under such conditions, perhaps improving sensorimotor gating relative to placebo. However, as reviewed elsewhere (Jacobson et al., 2018), effects of opioid drugs on prepulse inhibition in rodents are mixed, showing that additional systematic research is needed.

**Inhibition and effort**

The effects of blocking opioid receptors on response inhibition were investigated by Martin del Campo et al. (1992) using the Stroop task and more recently in a Stroop-like prime-probe task by van Steenbergen et al. (2017). The first study used a cumulative infusion of naloxone in 8 males and the other administered 50 mg naltrexone PO versus placebo in two groups of 26 female participants. Both studies revealed that overall Stroop performance was not affected by the pharmacological manipulation. Likewise, no significant effects were reported by the earlier described study by Zacny and de Wit on impulsive action, which investigated the effect of 5, 10, and 20 mg PO of oxycodone in six females and six males participants on stop-signal performance and go/no-go performance (Zacny & de Wit, 2009). The absence of clear findings on overall measures of response inhibition resonates with rodent studies that often find no or mixed effects of opioid manipulations on premature responding (Jacobson et al., 2018).

The study by van Steenbergen and colleagues also analyzed post-error and post-conflict adjustments in behavioral performance (2017), which are thought to reflect short-term adaptive increases in cognitive control triggered by aversive arousal integral to the task at hand (Botvinick, Braver, Barch, Carter, & Cohen, 2001; Dreisbach & Fischer, 2012; Inzlicht et al., 2015; van Steenbergen, 2015). Naltrexone was observed to increase reaction time slowing after participants made an error. This finding suggests that the aversive arousal associated with conflict and errors can be increased when endogenous opioid activity is blocked, which improves short-term adaptive cognitive control. On the other hand, chronic stress and depression is associated with hyperactive neural error monitoring, impairing post-error accuracy (Pizzagalli, 2011). Recent work in rodents has shown that a kappa-specific antagonist can ameliorate stress-induced post-error impairments (Beard et al., 2015). This illustrates that modulation of aversive arousal is not restricted to mu-opioid receptors (Valentino & Van Bockstaele, 2015).

Two studies have investigated the effect of the opioid system on perceived task difficulty and required effort. Grossman et al. (1984) reported a study that tested the effect of an opioid blockade (12.2 mg IV of naloxone) in six male participants performing a physical exercise task. This opioid antagonist increased the perceived difficulty of the task. Two further studies reported that opioid blockade abolished exercise-induced mood improvements (Allen & Coen, 1987; Daniel, Martin, & Carter, 1992), conceivably through increased perceived difficulty. Interestingly, a more recent study has observed that the opioid agonist oxycodone (10 mg PO) administered to 18 participants did not affect driving performance, whereas they did report increases in required effort while performing the task (Verster, Veldhuijzen, & Volkerts, 2006). This finding points to the possibility that compensatory effort (Hockey, 1997) might mask opioid-related impairment in performance on cognitive control tasks.

**Integrative discussion of the reviewed literature**

What can be learned from the budding literature on human opioid regulation of cognition and decision making? In light of the moderate to high density of mu-opioid receptors in the brain circuits involved in decision making and cognitive control (Figure 1), endogenous or drug modulation of mu-opioid receptors could exert direct modulatory effects on these
| Reference                                      | Sample                | Drug type  | Drug      | Route  | Dose                  | Max dose1 | Effect2 | Effect dose3 |
|------------------------------------------------|-----------------------|------------|-----------|--------|-----------------------|-----------|---------|--------------|
| Evans & Smith, 1964                           | 4F/M versus 4F/M      | Agonist    | Morphine  | PO     | 16 mg                 | low       | ↑       | low          |
| Zacny, Lichtor, Thapar, et al., 1994a          | 5F/7M                 | Agonist    | Morphine  | IV     | 10 mg                 | high      | ...     | ...          |
|                                                |                       | Partial    | Butorphanol| IV     | 0.5, 1, 2 mg           | high      | ...     | ...          |
| Zacny, Lichtor, Klafta, Alessi, & Apfelbaum, 1996a | 3F/7M                 | Agonist    | Codeine   | PO     | 60 mg Codeine/600 mg Acetaminophen | low       | ...     | ...          |
|                                                |                       | Mixed      | Butorphanol| TN     | 1, 2 mg               | high      | ...     | ...          |
| Zacny, Conley, & Galinkin, 1997a               | 5F/11M                | Agonist    | Morphine  | IV     | 10 mg                 | high      | ...     | ...          |
|                                                |                       | Mixed      | Buprenorphine | IV     | 0, 0.075, 0.15, 0.3   | high ↓    | high     | high         |
| Zacny, Conley, & Marks, 1997b                 | 4F/12M                | Agonist    | Morphine  | IV     | 10 mg                 | high      | ...     | ...          |
|                                                |                       | Mixed      | Nalbuphine | IV     | 2.5, 5, 10 mg         | high      | ...     | ...          |
| Walker & Zacny, 1998                          | 3F/9M                 | Agonist    | Codeine   | PO     | 60, 120 mg            | med       | ...     | ...          |
|                                                |                       | Agonist    | Morphine  | PO     | 20, 40 mg             | med       | ...     | ...          |
| Zacny, Hill, Black, & Sadeghi, 1998           | 15F/2M                | Agonist    | Hydromorphone | IV     | 0.33, 0.65, 1.3 mg   | high      | ...     | ...          |
|                                                |                       | Agonist    | Morphine  | IV     | 5, 10 mg              | high      | ...     | ...          |
| Walker & Zacny, 1999                          | 6F/10M                | Agonist    | Hydromorphone | IV     | Cumulative injections of: 33, 65, 1.3 mg | high      | ...     | ...          |
|                                                |                       | Agonist    | Meperidine | IV     | Cumulative injections of: 17.5, 35, 70 mg | high      | ...     | ...          |
|                                                |                       | Agonist    | Morphine  | IV     | Cumulative injections of: 2.5, 5, 10 mg | high      | ...     | ...          |
| Hill & Zacny, 2000                            | 5F/12M                | Agonist    | Hydromorphone | IV     | Cumulative injections of: 33, 65, 1.3 mg | high      | ...     | ...          |
|                                                |                       | Agonist    | Morphine  | IV     | Cumulative injections of: 33, 65, 1.3 mg | high      | ...     | ...          |
| Marsch et al., 2001                           | 18M                   | Agonist    | Morphine  | IV     | Three infusion rates (2 min bolus, 15 min, and 60 min) of 5, 10 mg | high      | ...     | ...          |
| Walker, Zacny, Galva, & Lichtor, 2001         | 5F/10M                | Agonist    | Morphine  | IV     | 2.5, 5, 10 mg         | high      | ...     | ...          |
|                                                |                       | Mixed      | Butorphanol| IV     | 0.5, 1, 2 mg          | med ↓     | med     |              |
|                                                |                       | Mixed      | Nalbuphine | IV     | Cumulative injections of: 2.5, 5, 10 mg | high      | ...     | ...          |
|                                                |                       | Mixed      | Pentazocine | IV     | 7.5, 15 mg            | low       | ...     | ...          |
| Zacny & Gutierrez, 2003                        | 9F/9M                 | Agonist    | Morphine  | PO     | 40 mg                 | med       | ...     | ...          |
|                                                |                       | Agonist    | Oxycodeine | PO     | 10, 20, 30 mg Oxycodeine | high      | ...     | ...          |
| Zacny, 2003                                   | 9F/9M                 | Agonist    | Hydrocodone | PO     | 5 mg Hydrocodone/1.5 mg Homatropine, 10 mg Hydrocodone/3 mg Homatropine | med ↓    | med     |              |
|                                                |                       | Agonist    | Morphine  | PO     | 40 mg                 | med ↓     | med     |              |
| Zacny & Gutierrez, 2008                        | 8F/8M                 | Agonist    | Hydrocodone | PO     | 5 mg Hydrocodone/325 mg Acetaminophen, 10 mg Hydrocodone/650 mg Acetaminophen | med ↓    | med     |              |
processes. Nevertheless, considering all reviewed evidence together, one striking observation is the abundance of pharmacological studies observing null effects. This is true in particular for the delay-discounting tasks, working memory task and overall measures of planning, switching, and inhibition. However, the majority of these studies have used only small to moderate sample sizes, which usually are only adequately powered to observe medium to high effect sizes. Considering that typical effects sizes in the field of psychology and affective neuroscience are small to moderate (Lakens & Evers, 2014; Poldrack et al., 2017), the majority of the published studies were underpowered to detect such effects. One conclusion that can be drawn is thus that new research in this area must take measures to improve statistical power. In the meantime, we advise caution in the interpretation of these null effects, in particular if the study used low or moderate doses of opioid agonists only.

Null effects reported after full (>90%) blockade of mu-opioid receptors are an intermediate case, since valuable information can indeed be gleaned by observing behaviors unaltered or only partly diminished when opioid signaling is blocked. For instance, it is striking that healthy people display comparable working memory capacity and cognitive flexibility after treatment with opioid agonists, antagonists, and placebo. Similarly, although several studies report reduced reward pleasantness after naloxone or naltrexone, healthy humans consistently report substantial enjoyment of rewards when mu-opioid receptors are fully blocked. The clearest patterns indicating opioid modulation of performance emerged for value-based learning and decision-making tasks, the DSST, and the logical reasoning task. We will elaborate on these results below and highlight potential neural mechanisms.

**Reward-based decision-making**

The reviewed evidence from studies of reward-based decision-making in humans is largely consistent with opioid regulation of reward motivation, as measured by effort invested to obtain relatively high-value rewards (Chelnokova et al., 2014; Eikemo et al., 2017; Weber et al., 2016). Extensive evidence from non-human animals indicates a parallel mechanism (Mahler & Berridge, 2012; S. Peciña & Berridge, 2013). We speculate that the rewarding effects of exerting physical effort during exercise (Allen & Coen, 1987; Daniel et al., 1992; Grossman et al., 1984; Hiura et al., 2017; Saanijoki et al., 2018) or cognitive effort (Inzlicht, Shenhav, & Olivolia, 2018) may be mediated by the opioid system. Note that the existing literature in healthy humans does not allow us to disentangle the decision processes involved in weighing costs, such as effort expenditure, against gains, such as social, monetary, or taste rewards.
Table 3  Pharmacological studies reporting effect on working memory

| Reference                          | Sample | Drug type | Drug          | Route | Dose          | Max dose | Effect1 | Effect2 | Effect3 |
|------------------------------------|--------|-----------|---------------|-------|---------------|----------|---------|---------|---------|
| Evans & Smith, 1964                | 4F/M versus 4F/M | Agonist | Morphine | PO | 16 mg | low | ... | ... | ... |
| Ghoneim, Mewaldt, & Thatcher, 1975 | 10M    | Agonist | Fentanyl | IV | 0.1, 0.2 mg | high | ↓ high | ↓ high | ↓ high |
| Volavka, Dombush, Malya, & Cho, 1979 | 26M    | Agonist | Fentanyl | IV | 0.1, 0.2 mg | high | ... | ... | ... |
| File & Silverstone, 1981           | 6F/6M  | Antagonist | Naloxone | IV | 10, 20 mg | -med | ... | ... | ... |
| Cohen, Murphy, Cohen, Weingartner, & Pickar, 1983 | 3F/4M  | Antagonist | Naloxone | IV | 21, 70, 140 mg | -high | ... | ... | ... |
| Székely, Török, Karczag, Tolma, & Till, 1986 | 8M     | Agonist | DiHydrocodeine | SC | 20 mg | low | ↑ low | ↓low | ... |
| Saarialho-Kere, Mattila, & Seppälä, 1988 | 11F/M  | Mixed agonist | Pentazocine | IM | 30 mg | med | ... | ... | ... |
| MacDonald, Gough, Nicoll, & Dow, 1989 | 12M    | Mixed agonist | Buprenorphine | IM | 0.3 mg | high | ... | ... | ... |
| Martin del Campo, McMurray, Besser, & Grossman, 1992 | 8M     | Agonist | Naloxone | IV | Cumulative infusion: 10-mg bolus of Naloxone was given as a rapid bolus, followed by an infusion of 7 mg/hr for 12 hr | -med | ↓ med | ↓ med | ↓ med |
| Hanks, O’Neill, Simpson, Wesnes, & A, 1995 | 4F/8M  | Agonist | Codeine | PO | 10, 15 mg | low | ... | ... | ... |
| Zacny, Lichtor, Klafla, Aessi, & Apfelbaum, 1996a | 3F/7M  | Mixed agonist | Butorphanol | TN | 1, 2 mg | high | ... | ... | ... |
| Black, Hill, & Zacny, 1999         | 2F/8M  | Agonist | Alfentanil | IV | 16, 32, 64 ng/ml | high | ... | ... | ... |
| Zacny & Goldman, 2004              | 9F-9M  | Agonist | Remifentanil | IV | Continuous infusion: 0.75, 1.5, 3 ng/ml | high | ... | ... | ... |
| Verster, Veldhuijzen, & Volkerts, 2006 | 12F/6M | Agonist | Propoxyphene napsylate | PO | 50, 100, 200 mg | med | ... | ... | ... |
| Friswell et al., 2008              | 9F-9M  | Agonist | Morphine | PO | 5 mg Oxycodone/325 mg Acetaminophen, 10 mg Oxycodone/650 mg Acetaminophen | low | ... | ... | ... |
| Quednow, Csomor, Chmiel, Beck, & Vollenweider, 2008 | 18M    | Agonist | Morphine | PO | 10 mg | high | ... | ... | ... |

F = female; M = male participants. Studies used within-subject designs unless otherwise noted.

1 Estimated dose for agonists based on morphine equivalent of the maximum dose of in the respective study. For antagonist drugs, the estimated dose is preceded by a minus. See caption of Figure 2 for more details.

2 Arrow indicates significantly improved (↑), impaired (↓), mixed effects (↕) or null-effects (…) on performance relative to a placebo control condition.

3 Minimum estimated dose at which the indicated effect is significantly different from placebo.
The current literature also points to a modest opioid modulation of the rewarding experience (liking) of high-value stimuli, but so far there is little evidence of a change in the neural response of winning money in healthy humans. One of the studies reviewed also points to opioid modulation of (monetary) reward learning (Efremidze et al., 2017). Overall, however, findings are in line with the notion that mu-opioid receptor stimulation by endogenous and exogenous opioid peptides causes a shift in valuation along a *hedonic gradient* ranging from unpleasant to pleasurable. As illustrated in Figure 4, we suggest that increased enjoyment of and motivation towards rewarding stimuli could underlie the observed changes in decision making. Studies in both rodents and humans indicate that these effects may be most pronounced for highly salient stimuli, such as high-value rewards. Notably, these studies consistently show that blocking more than 90% of mu-opioid receptors does not obliterate the appreciation of a rewarded choice and only moderately reduces the pleasantness of rewards in general. Interestingly, while there is strong evidence that opioid drugs enhance food-liking responses in rodents, mu-opioid antagonism directly into *hedonic hotspots* did not suppress such responses.

### Table 4  Pharmacological studies reporting effect on mathematical skills

| Reference                     | Sample                  | Drug type | Drug    | Route | Dose         | Max dose1 | Effect1 | Effect2 | Effect3 |
|-------------------------------|-------------------------|-----------|---------|-------|--------------|-----------|---------|---------|---------|
| Kornetsky, Humphries, & Evans, 1957 | 4F/6M                   | Agonist   | Meperidine | PO    | 50, 100 mg  | low       |         |        |         |
| Smith, Semke, & Beecher, 1962 (Study 1) | 2M                      | Agonist   | Morphine  | SC    | 10 mg       | high      | ↓ high  | ↓ high  | ↑ high  |
| Smith, Semke, & Beecher, 1962 (Study 2) | 2M                      | Agonist   | Morphine  | SC    | 10 mg       | high      | ↓ high  | ↓ high  | ↑ high  |
| Martin del Campo, McMurray, Besser, & Grossman, 1992 | 8M                      | Agonist   | Naloxone  | IV    | Cumulative infusion: 10-mg bolus was given as a rapid bolus, followed by an infusion of 7 mg/hr for 12 hr | med       | ↓ high  | ↓ high  | ↑ high  |
| Cleeland et al., 1996         | 5F/2M versus 2F/6M versus 5F/3M versus 3F/5M | Agonist   | Morphine  | PO    | 15, 20, 25, 30 mg | med       |         |        |         |

F = female; M = male participants. Studies used within-subject designs unless otherwise noted.

1 Estimated dose for agonists based on morphine equivalent of the maximum dose of in the respective study. For antagonist drugs, the estimated dose is preceded by a minus. See caption of Figure 2 for more details.

2 Arrow indicates significantly improved (↑), impaired (↓), mixed effects (↕) or null-effects (….) on performance relative to a placebo control condition.

3 Minimum estimated dose at which the indicated effect is significantly different from placebo.
Opioid agonists might similarly attenuate the negative value of punishments, although the exact nature of this modulation requires extensive future research. For example, there is some evidence that opioid drugs may modulate large and small punishments to the same extent (Atlas et al., 2014; Gospic et al., 2007; Murray et al., 2014; Petrovic et al., 2008; Price, Harkins, Rafii, & Price, 1986; Schoell et al., 2010). Moreover, despite the relief opioid drugs can provide for acute clinical and experimental pain (Wanigasekera et al., 2012), psychosocial stress (Bershad et al., 2015, 2018), certain depressive symptoms (Peciña et al., 2018), and feelings of breathlessness (Hayen et al., 2017), opioid blockade does not consistently increase the aversiveness of experimental pain (Anderson et al., 2002; Berna et al., 2018; Eippert et al., 2008; Grevert & Goldstein, 1977). Clearly, more well-powered psychopharmacological evidence is needed to understand opioid modulation of reward and punishment processes, as well as their integration in the human brain.

**Cognitive control**

With respect to the cognitive control domain, studies showed the most consistent effects (the highest proportion of significant effects) for the coding task (DSST). This is also the task that has been most frequently included in opioid drug studies. At moderate and high opioid drug doses, clear impairments on performance have been observed in many studies using this task (Figure 3). Although the DSST is often used as a primary measure of psychomotor skills, recent work using a factorial-analytic approach suggest that performance on the DSST does not rely on basic psychomotor speed but instead relies on several executive function processes including working memory updating, switching, and inhibition (Knowles et al., 2015). This task might require a delicate coordination and integration of these different control processes. It could be speculated that this has rendered the DSST, and to a lesser extent logical reasoning, the most sensitive measures of cognitive control impairment. On the other hand, no evidence exists that blocking opioids enhances coding or logical reasoning performance in healthy people, which speaks against involvment of the endogenous opioid system as a key mechanism in executive functions. Indeed, other tasks in the cognitive domain, which are typically constructed to tap into a single subtype of control processes, were not associated with strong effects of opioid drugs or blockade. Combined, these results indicate that the effects of opioid drugs at moderate to high doses will be particularly strong for tasks which require the orchestration of multiple cognitive control functions relying on different regions in frontoparietal brain circuits. However, given the sparse data on cognitive measures other than DSST and logical reasoning, future research is warranted before firm conclusions can be drawn regarding the effects of opioids on these measures.

**Working hypothesis: Enhanced cognitive performance after opioid-reduced aversive arousal?**

Some evidence suggests that opioid agonist administration relative to placebo can also improve rather than impair performance. This was for example observed for logical reasoning and DSST performance in early studies by Evans and colleagues (Evans & Smith, 1964; Evans & Witt, 1966) as well as in more recent work on intradimensional set shifting and attention (Quednow et al., 2008). These studies have in common that they used low doses of morphine (or codeine). One possible explanation for these findings might be that low doses of opioid agonists could reduce the aversive arousal (Thayer, 1989) or distress associated with a task. If the relationship between aversive arousal and cognitive control follows an inverted U-shape, as previous work has proposed (van Steenbergen, Band, & Hommel, 2015), low doses of opioid agonist drugs might compensate for arousal-induced impairment that occurs in the placebo condition (Figure 5). Opioids indeed tend to reduce arousal and can cause sedation at high doses. Even at lower doses, opioid agonists in humans and some other species reduce pupil size (miosis) (Lee & Wang, 1975; Murray, Adler, & Korczyn, 1983). In addition, opioid antagonism increases cortisol responses, and this is thought to reflect blockade of a tonic endogenous opioid inhibition of cortisol in humans (Lovallo et al., 2015).

![Fig. 5 U-shaped relationship between aversive arousal and cognitive control. Opioids agonist might reduce aversive arousal (white), whereas opioid antagonist might increase it (black). According to this hypothesis, drug effects on cognition depend on the baseline level of aversive arousal, such that an opioid agonist might improve performance in high stress contexts, yet impair performance under low stress.](image-url)
The view that a low opioid drug dose could enhance cognitive performance by reducing aversive arousal also dovetails with recent rodent work on stress-allievating properties of opioids (Valentino & Van Bockstaele, 2015). Endogenous opioid brain activation in response to stress might similarly help to prevent stress-induced impairments (Shields et al., 2016), as indeed suggested in some human (Bandura, Cioffi, Taylor, & Brouillard, 1988) and animal studies (Laredo et al., 2015). This view agrees with prior work that shows that cognitive control tasks elicit affective responses (i.e., integral emotions; Inzlicht et al., 2015), which might drive (mal) adaptive behavior (Botvinick, 2007; van Steenbergen et al., 2009) and which are likely under opioid regulation (van Steenbergen et al., 2017). Another possibility to consider is that cognitive improvements after low doses of opioids are caused by increases in appetitive motivation or learning. Such effects are particularly likely when the task itself involves external rewards (Eikemo et al., 2017) or when performance on tasks is perceived to reflect intelligence or capability. In addition, tasks perceived to be of high relevance might also generate internal “pseudo-rewards” (Holroyd & Yeung, 2012; Ribas-Fernandes et al., 2011), in particular when effort is intrinsically valuable (Inzlicht et al., 2018).

Given these considerations, it is plausible that cognitive control, just like decision-making, is modulated by opioids via brain networks involved in valuation, saliency, and motivation, shifting the cost-benefit trade-off, which in turn determines allocation of cognitive control (Shenhav, Botvinick, & Cohen, 2013). In addition, prefrontal networks involved in maintaining task-goal representations might be modulated directly via binding to its opioid receptors. In line with this suggestion, a recent PET study observed that high mu-opioid signaling (lower binding potential) in a ventral region of the lateral prefrontal cortex was positively related to performance on the Wisconsin Card Sorting Test in a group of patients with major depressive disorder (Light et al., 2017; Shenhav et al., 2017). A possible mechanism at a neuronal level could be that stimulation of mu-opioid receptors suppresses interneuron spiking and increases glutamate-coded output of prefrontal neurons at multiple projection targets, which in turn might engender disorganized control and decision processes (Baldo, 2016).

**Directions for future research**

The previous section provided some initial insights into the role of the mu-opioid system in higher-level cognitive function. Yet, numerous issues require future investigation. One unresolved challenge is that opioids might reduce cortical signaling without directly affecting performance in cognitive tasks, because participants use strategies to compensate for these deficits (Hockey, 1997). Future studies should include physiological measures, such as cardiovascular measures (Gendolla, Wright, & Richter, 2011; Kuipers et al., 2017; Spruit, Wilderjans, & van Steenbergen, 2018) and task-evoked pupil dilation (Kahneman, 1973; van der Wel & van Steenbergen, 2018) to investigate potential compensatory mechanisms. In addition, behavioral impairments in control tasks might reflect shifts in motivation instead of reflecting a cognitive incapability (Kurzban, Duckworth, Kable, & Myers, 2013; Shenhav et al., 2017). As we alluded to earlier, cognitive control shares many processes and brain circuits that also are important for value-based decision making, and future studies are warranted to understand the role of opioids in these processes (Berkman, Hutcherson, Livingston, Kahn, & Inzlicht, 2017).

Although opioid agonist drugs do not typically produce strong subjective effects at low doses (Hanks, O’Neill, Simpson, Wenes, 1995), changes in self-reported mood and arousal are typically reported in many of the studies reviewed, most consistently at higher doses. The evidence for mood effects from opioid blockade on the other hand, is much less compelling (Berna et al., 2018; Eippert et al., 2008; Grevert & Goldstein, 1977). Interestingly, mood induction tasks appear to modulate endogenous opioid neurotransmission (Koepf et al., 2009; Prossin et al., 2015; Zubieta et al., 2003). One important avenue for future research is to understand the role of affective and motivational states in altered cognitive function. For example, studies might investigate whether variation in receptor binding potential or drug-induced changes in subjective state correlate with behavioral outcomes (Light et al., 2017; Weber et al., 2016). Researchers investigating the effect of hedonic states on cognitive control and decision making (Dreisbach & Goschke, 2004; Isen & Means, 1983; van Steenbergen, Band, & Hommel, 2010; Van Steenbergen, Band, Hommel, Rombouts, & Nieuwenhuis, 2015) and the influence of motivation on these processes (Botvinick & Braver, 2015; Braver et al., 2014; Pessoa, 2009) could use antagonist drugs to determine the role of endogenous mu-opioid neurotransmission in these effects. On a related note, more broadly defined control processes, such as mental flexibility and creativity, often have been related to positive affective states (Ashby, Isen, & Turken, 1999). It would be interesting to assess the role of the opioid system in these processes as well (Streufert & Gengo, 1993; Zacny, 1995).

Opioid administration at higher doses can produce other subjective effects that may influence task performance, such as nausea, difficulty concentrating, or sedation (Zacny & de Wit, 2009). Aversive side-effects could counteract a positive hedonic shift induced by opioid agonists or inflate the negative shift induced by opioid antagonism. Drowsiness and feeling spaced out from large opioid drug doses could also directly impact performance on cognitive and value-based tasks. Such confounds can be avoided by employing smaller drug doses (counteracting any loss in statistical power, e.g., by
increasing sample sizes) or by employing active placebo treatments to ensure that drug conditions are matched on relevant side effects. In addition, future research could draw inspiration from anecdotal evidence that opioids can induce pain asymbolia, i.e., intact detection of pain but without the affective-motivational component (Berthier, Starkstein, & Leiguarda, 1988). Studies might therefore implement measures of motivation/detachment to measure the effects of opioid drugs on engagement with cognitive and decision-making tasks.

Another unresolved question relates to context and counterfactual outcomes. Do opioid drugs modulate high-value reward processes equally in the presence of punishments, such as pain or possible economic loss? As recently observed by Buchel et al. (2018), opioid blockade reduced pleasantness ratings of erotic stimuli significantly more than ratings of monetary wins. It is unclear whether the inclusion of highly salient erotic stimuli reduced the relative value of money during the experiment. As for tasks including punishments as well as rewards, it is possible that mu-opioid stimulation would cause a shift primarily of aversive stimuli but not rewards, because aversive stimuli are typically more salient (Kahneman & Tversky, 1979). Naloxone increased aversiveness of economic loss but not economic gain in Petrovic et al. (2008). Kut et al. (2011) found effects of naloxone on pain but not on pleasantness ratings of erotic stimuli. Also, two studies have reported decreased pleasantness of opioid drug effects during physical pain (Conley, Toledano, Apfelbaum, & Zacny, 1997; Zacny, McKay, et al., 1996b; but see Comer, Sullivan, Vosburg, Kowalczyk, & Houser, 2010). Studies including both positive and negative facial expressions provide mixed evidence, however, with opioid drug effects preferentially observed for negative or positive affective stimuli in different studies. (Bershad et al., 2016; Losoph et al., 2018; Syal et al., 2015; Wardle et al., 2016). Moreover, Berna et al. (2018) reported the largest naloxone reduction in pleasantness of the best possible (yet still painful) outcome, indicating that relative relief is opioid-dependent. Well-powered studies, including both rewarding and aversive outcomes, are needed to resolve these inconsistencies. In addition, opioid effects on value-based decision making should also be addressed during ongoing pain (Gandhi, Becker, & Schweinhardt, 2013) or other opioid-sensitive aversive states.

Although opioid drugs can exert direct effects on mu-opioid receptors expressed in the important hubs of the neural decision-making and cognitive-control networks (Figure 1), they can also act indirectly via other neurotransmitters. For example, the canonical disinhibition model of Johnson and North (1992) proposed that opioid drugs induce reward via increased dopamine signaling due to opioid inhibition of GABA interneurons in the ventral tegmental area. More recent work has shown that we are only at an early stage of understanding the exact role of dopamine signaling for opioid drug effects (Badiani, Belin, Epstein, Calu, & Shaham, 2011; Corre et al., 2018; Nutt, Lingford-Hughes, Erritzoe, & Stokes, 2015). For instance, mu-opioid receptor activation can have a net excitatory or net inhibitory effect on VTA neurons depending on a variety of pre- and postsynaptic mechanisms (Fields & Margolis, 2015). Furthermore, dopamine modulates cognition via different receptor types and pathways (Bromberg-Martin, Matsumoto, & Hikosaka, 2010; Cools, 2015), making direct comparisons difficult. The available evidence renders it unlikely that effects of opioid drugs can simply be explained in terms of dopaminergic modulation alone. Rodent findings that mu-opioids and dopamine play functionally different roles in the hedonic and motivational properties of reward (Berridge, 2007) need further examination in humans. For instance, some studies are beginning to manipulate opioids and dopamine pharmacologically using the same tasks (Porchet et al., 2013; Weber et al., 2016) or even combining an agonist for one system with an antagonist for the other (Jayaram-Lindström et al., 2017; Jayaram-Lindström, Wennberg, Hurd, & Franck, 2004; Roche et al., 2017).

The mu-opioid system also interacts with other neurotransmitters systems. For example, interactions between opioids and the locus-coeruleus-norepinephrine system are well-documented (Armsten et al., 1981; Chajjale et al., 2013), and futures studies might investigate whether opioid drugs modulate cognitive processing via norepinephrine. There is also evidence that the endocannabinoid system interacts with opioid mechanisms that support reward (Rowland, Mukherjee, & Robertson, 2001; Solinas & Goldberg, 2005).

In addition to the literature reviewed, there is increasing evidence of opioid involvement in psychopathology. For example, chronic opioid antagonist administration may increase cognitive control and decrease the value of reinforcers in different patient groups (Lobmaier, Kunøe, Gossop, & Waal, 2011), and there is some evidence for dysregulation of mu-opioid receptor function across addictions (Ghitza et al., 2010; Mick et al., 2016). While chronic opioid misuse has been associated with maladaptive decisions (Giordano et al., 2002; Landes, Christensen, & Bickel, 2012), prolonged opioid blockade can reduce craving and drug taking in individuals with substance use disorder (Johnson, 2006; Mouaffak et al., 2017; Tanum et al., 2017). Interestingly, in addition to reducing craving and relapse in addiction, opioid blockade may reduce impulsive behaviors in kleptomania, pathological gambling, and “sex addiction” (Bostwick & Bucci, 2008; Grant, Kim, & Odlaug, 2009; Johnson, 2006; Lahti, Halme, Pankakoski, Sinclair, & Alho, 2010; Minozzi et al., 2011; Porchet et al., 2013; Rukstalis et al., 2005; Stotts, Dodrill, & Kosten, 2009). In a different line of research, recent work has suggested that opioid agonists might reduce depressive symptoms (Ehrich et al., 2015; Fava et al., 2016; Stanciu, Glass, & Penders, 2017; Yovell et al., 2016) and influence anhedonia.
(Barch, Pagliaccio, & Luking, 2015; Treadway, Bossaller, Shelton, & Zald, 2012), providing possible new avenues to treat patients with mood disorders.

Conclusions

The present review supports a role for the opioid system in modulating some key aspects of cognitive control and decision-making. We have shown that the effects of reward-based decision-making by opioid drugs might be driven by a shift in valuation processes. At higher doses, opioid agonists can impair performance on neuropsychological executive function tasks involving coding and logical reasoning. At lower doses opioids can improve cognitive function, and the working hypothesis proposed suggests that these effects are driven by opioid-induced reduction of aversive arousal. We hope that this review provides an initial roadmap for future research to gain a better understanding of how opioids modulate cognition, affect, and their interactions.

Acknowledgements The authors are grateful for helpful discussions with Gernot Ernst and Daniel Castro. They thank Lauri Nummenmaa for providing the binding potential PET image from his lab (shown in Figure 1). They are grateful to Guro Løseth for valuable comments on the manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Allen, M. E., & Coen, D. (1987). Naloxone blooding of running-induced mood changes. Annals of Sports Medicine, 3, 190–195.

Anderson, W. S., Sheth, R. N., Bencherif, B., Frost, J. J., & Campbell, J. N. (2002). Naloxone increases pain induced by topical capsaicin in healthy human volunteers. Pain, 99, 207–216.

Arnstien, A. F. T., Neville, H. J., Hillyard, S. A., Janowsky, D. S., Salk, T., Diego, S., … May, R. (1984). Naloxone selective increases information measures processing in humans. Journal of Neuroscience, 4, 2912–9.

Arnstien, A. F. T., Segal, D. S., Loughlin, S. E., Roberts, D. C. S., Jolla, L., & Diego, S. (1981). Evidence for an interaction of opioid and noradrenergic locus coeruleus systems in the regulation of environmental stimulus-directed behavior. Brain Research, 222, 351–363.

Arnstien, A. F. T., Segal, D. S., Neville, H. J., Hillyard, S. A., Janowsky, D. S., Judd, L. L., & Bloom, F. E. (1983). Naloxone augments electrophysiological signs of selective attention in man. Nature, 304, 725–727.

Asbhy, F. G., Isem, A. M., & Turken, A. U. (1999). A neuropsychological theory of positive affect and its influence on cognition a neuropsychological theory of positive affect and its influence on cognition. Psychological Review, 106, 529–550.

Aston-Jones, G., & Cohen, J. D. (2005). An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annual Review of Neuroscience, 28, 403–450.

Atlas, L. Y., Wielgosz, J., Whittington, R. A., & Wager, T. D. (2014). Specifying the non-specific factors underlying opioid analgesia: Expectancy, attention, and affect. Psychopharmacology, 231, 813–823.

Badiani, A., Belin, D., Epstein, D., Calu, D., & Shaham, Y. (2011). Opiate versus psychostimulant addiction: the differences do matter. Nature Reviews Neuroscience, 12, 685–700.

Bald, B. A. (2016). Prefrontal cortical opioids and dysregulated motivation: A network hypothesis. Trends in Neurosciences, 39, 366–377.

Bandura, A., Cioffi, D., Taylor, C. B., & Brouillard, M. E. (1988). Perceived self-efficacy in coping with cognitive stressors and opioid activation. Journal of Personality and Social Psychology, 53, 479–488.

Barbano, M. F., & Cador, M. (2007). Opioids for hedonic experience and dopamine to get ready for it. Psychopharmacology, 191, 497–506.

Barch, D. M., Pagliaccio, D., & Luking, K. (2015). Mechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophrenia. In Behavioral neuroscience of motivation (pp. 411–449), Springer.

Bartra, O., McGuire, J. T., & Kable, J. W. (2013). The valuation system: A coordinate-based meta-analysis of BOLD fMRI experiments examining neural correlates of subjective value. NeuronImage, 76, 412–427.

Beard, C., Donahue, R. J., Dillon, D. G., Van’t Veer, A., Webber, C., Lee, J., … Carroll, F. I. (2015). Abnormal error processing in depressive states: a translational examination in humans and rats. Translational Psychiatry, 5, e564.

Berkman, E. T., Huchterson, C. A., Livingston, J. L., Kahn, L. E., & Inzlicht, M. (2017). Self-control as value-based choice. Current Directions in Psychological Science, 26, 422–428.

Berna, C., Leknes, S., Ahmad, A. H., Mhuircheartaigh, R. N., Goodwin, G. M., & Tracey, I. (2018). Opioid-independent and opioid-mediated modes of pain modulation. Journal of Neuroscience, 38, 9047–9058.

Berridge, K. C. (2007). The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology, 191, 391–431.

Berridge, K. C., & Kringelbach, M. L. (2015). Pleasure systems in the brain. Neuron, 86, 646–664.

Berridge, K. C., Robinson, T. E., & Aldridge, J. W. (2009). Dissecting components of reward: “liking”, “wanting”, and learning. Current Opinion in Pharmacology, 9, 65–73.

Bershad, A. K., Jaffe, J. H., Childs, E., & de Wit, H. (2015). Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. Psychoneuroendocrinology, 52, 281–288.

Bershad, A. K., Miller, M. A., Norman, G. J., & de Wit, H. (2018). Effects of opioid-and non-opioid analgesics on responses to psychosocial stress in humans. Hormones and Behavior, 102, 41–47.

Bershad, A. K., Seiden, J. A., & de Wit, H. (2016). Effects of buprenorphine on responses to social stimuli in healthy adults. Psychoneuroendocrinology, 63, 43–49.

Bertlher, M., Starkstein, S., & Leiguarda, R. (1988). Asymptopia for pain: A sensory-limbic disconnection syndrome. Annals of Neurology, 24, 41–49.

Bickel, W. K., Yi, R., Landes, R. D., Hill, F. P., & Baxter, C. (2011). Remember the future: Working memory training decreases delay discounting among stimulant addicts. Biological Psychiatry, 69, 260–265.

Black, M. L., Hill, J. L., & Zaczek, J. P. (1999). Behavioral and physiological effects of remifentanil and alfentanil in healthy volunteers. Anesthesia, 90, 718–726.

Boettger, C. A., Kelley, E. A., Mitchell, J. M., D’Esposito, M., & Fields, H. L. (2009). Now or later? An fMRI study of the effects of
endogenous opioid blockade on a decision-making network. *Pharmacology Biochemistry and Behavior*, 93, 291–299.

Bostwick, J. M., & Bucci, J. A. (2008). Internet sex addiction treated with naltrexone. *Mayo Clinic Proceedings*, 83, 226–230.

Botvinick, M. M. (2007). Conflict monitoring and decision making: Reconciling two perspectives on anterior cingulate function. *Cognitive Affective & Behavioral Neuroscience* 7, 356–366.

Botvinick, M. M., & Braver, T. S. (2015). Motivation and cognitive control: From behavior to neural mechanism. *Annual Review of Psychology*, 66, 83–113.

Botvinick, M. M., Braver, T. S., Barch, D. M. M., Carter, C. S. S., & Cohen, J. D. D. (2001). Conflict monitoring and cognitive control. *Psychological Review*, 108, 624–652.

Bradley, C. M., & Nicholson, A N. (1986). Effects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man. *British Journal of Clinical Pharmacology*, 22, 507–12.

Bradley, C. M., & Nicholson, A N. (1987). Studies on performance with aspirin and paracetamol and with the centrally acting analgesics meptazinol and pentazocine. *European Journal of Clinical Pharmacology*, 32, 135–139.

Braver, T. S., Krug, M. K., Chiew, K. S., Kool, W., Westbrook, J. A., Clement, N. J., … Somerville, L. H. (2014). Mechanisms of motivation-cognition interaction: challenges and opportunities. *Cognitive, Affective & Behavioral Neuroscience*, 443–472.

Bromberg-Martin, E. S., Matsumoto, M., & Hikosaka, O. (2010). Dopamine in motivational control: Rewarding, aversive, and alerting. *Neuron*, 68, 815–834.

Buchel, C., Miedl, S., & Sprenger, C. (2018). Hedonic processing in humans is mediated by an opioidergic mechanism in a mesocorticolimbic system. *ELife*, 7:e39648.

Calo, G., Guerrini, R., Rizzi, A., Salvadori, S., & Regoli, D. (2000). Pharmacology of nociceptin and its receptor: a novel therapeutic target. *British Journal of Pharmacology*, 129, 1261–1283.

Castro, D. C., & Berridge, K. C. (2017). Opioid and orexin hedonic hotspots in rat orbitofrontal cortex and insula. *Proceedings of the National Academy of Sciences*, 114, E9125–E9134.

Chaijale, N. N., Curtis, A. L., Wood, S. K., Zhang, X. Y., Bhatnagar, S., Reyes, B. A., … Valentino, R. J. (2013). Social stress engages opioid system promotes visual attention to faces and eyes. *Neuron*, 746, 139–145.

Chelnokova, O., Laeng, B., Eikemo, M., Riegsel, J., Lesoth, G., Maurud, H., … Leknes, S. (2014). Rewards of beauty: the opioid system mediates social motivation in humans. *Molecular Psychiatry*, 19, 746–747.

Chelnokova, O., Laeng, B., Lesoth, G., Eikemo, M., Willoch, F., & Leknes, S. (2016). The μ-opioid system promotes visual attention to faces and eyes. *Social Cognitive and Affective Neuroscience*, 11, 1902–1909.

Cherrier, M. M., Amory, J. K., Ersek, M., Risler, L., & Shen, D. N. (2009). Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults. *Journal of Pain*, 10, 1038–1050.

Chiew, K. S., & Braver, T. S. (2011). Positive affect versus reward: emotional and motivational influences on cognitive control. *Frontiers in Psychology*, 2, 279.

Cleeland, C. S., Nakamura, Y., Howland, E. W., Morgan, N. R., Edwards, K. R., & Backonja, M. (1996). Effects of oral morphine on cold pressor tolerance time and neuropsychological performance. *Neuropsychopharmacology*, 15, 252–62.

Cohen, R. M., Murphy, D. L., Cohen, R., Weingartner, H., & Pickar, D. (1983). High-dose naloxone affects task performance in normal subject, 36, 127–136.
Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., De Somer, M., ... & Richards, J. B. (2004). Effects of morphine and naltrexone on physiological effects of intravenous hydromorphone and morphine healthy volunteers. *Psychopharmacology*, 152, 31–39.

Hiura, M., Sakata, M., Ishii, K., Toyohara, J., Oda, K., Nariai, T., & Ishiwata, K. (2017). Central µ-opioidergic system activation evoked by heavy and severe-intensity cycling exercise in humans: a pilot study using positron emission tomography with 11C-Carfentanil. *International Journal of Sports Medicine*, 38, 19–26.

Hockey, G. R. J. R. (1997). Compensatory control in the regulation of human performance under stress and high workload: A cognitive-energetic framework. *Psychological Biology*, 45, 73–93.

Holroyd, C. B., & Yeung, N. (2012). Motivation of extended behaviors by anterior cingulate cortex. *Trends in Cognitive Sciences*, 16, 122–128.

Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Wang, H., ... & Zubieta, J. K. (2013). Response of the µ-opioid system to social rejection and acceptance. *Molecular Psychiatry*, 18, 1211–1217.

Inzlicht, M., Bartholow, B. D., & Hirsh, J. B. (2015). Emotional foundations of cognitive control. *Trends in Cognitive Sciences*, 19, 1–7.

Inzlicht, M., Shenhav, A., & Olivola, C. Y. (2018). The effort paradox: Effort is both costly and valued. *Trends in Cognitive Sciences*, 22, 337–349.

Isten, A. M., & Means, B. (1983). The influence of positive affect on decision-making strategy. *Social Cognition*, 2, 18–31.

Jääskeläinen, I. P., Hirvonen, J., Kujala, T., Alho, K., Eriksson, C. J. P., Lehtokoski, A., ... & Sillanaukee, P. (1998). Effects of naltrexone and ethanol on auditory event-related brain potentials. *Alcohol*, 15, 105–111.

Jacobi, J. J. C., Michaud, G. M., & Tremblay, E. C. (1979). Mixed agonist-antagonist opiates and physical dependence. *British Journal of Clinical Pharmacology*, 7, 291S–296S.

Jacobson, M. L., Wulf, H. A., Browne, C. A., & Lucki, I. (2018). Opioid modulation of cognitive impairment in depression. In S. O’Mara (Ed.), Progress in brain research (1st ed., Vol. 239, pp. 1–28). Amsterdam: Elsevier B.V.

Jarvik, L. F., Simpson, J. H., Guthrie, D., & Liston, E. H. (1981). Dopamine release following chronic, but not acute amphetamine and a cholecystokinin agonist. *Psychopharmacology*, 65, 600–606.

Grevirt, P., & Zaczynski, J. P. (2000). Comparing the subjective, psychomotor, physiological effects of intravenous hydromorphone and morphine healthy volunteers. *Psychopharmacology*, 152, 31–39.
Nummenmaa, L., Saanijoki, T., Tuominen, L., Hirvonen, J., Tuulari, J. J., Nuutila, P., & Kalliokoski, K. (2018). Mu-opioid receptor system mediates reward processing in humans. *Nature Communications*, 9, 1500.

Nummenmaa, L., & Tuominen, L. (2018). Opioid system and human emotions. *British Journal of Pharmacology*, 175, 2737–2749.

Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., & Stokes, P. R. (2015). The dopamine theory of addiction: 40 years of highs and lows. *Nat Rev Neurosci*, 16, 305–312.

Oliveto, A. H., Bickel, W. K., Kamien, J. B., Hughes, J. R., & Higgins, S. T. (1994). Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure. *Psychopharmacology*, 114, 417–423.

Parker, L. A., Maier, S., Rennie, M., & Crebolder, J. (1992). Morphine- and naltrexone-induced modification of palatability: Analysis by the taste reactivity test. *Behavioral Neuroscience*, 106, 999–1010.

Pasternak, G. W. (2001). Insights into mu opioid pharmacology: The role of mu opioid receptor subtypes. *Life Sciences*, 68, 2213–2219.

Pattij, T., Scheters, D., Janssen, M. C. W., Wiskerke, J., & Schoffelmeer, A. N. M. (2009). Acute effects of morphine on distinct forms of impulsive behavior in rats. *Psychopharmacology*, 205, 489–502.

Peciña, M., Karp, J. F., Mathew, S., Todenkopf, M. S., Ehrich, E. W., & Zubieta, J. K. (2019). Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. *Molecular Psychiatry*, 24, 576–587.

Peciña, S., & Berridge, K. C. (2013). Dopamine or opioid stimulation of nucleus accumbens similarly amplify cue-triggered “wanting” for reward: Entire core and medial shell mapped as substrates for PIT enhancement. *European Journal of Neuroscience*, 37, 1529–1540.

Peciña, S., & Smith, K. S. (2010). Hedonic and motivational roles of opioids in food reward: Implications for overeating disorders. *Pharmacology Biochemistry and Behavior*, 97, 34–46.

Pessoa, L. (2009). How do emotion and motivation direct executive control? *Trends in Cognitive Sciences*, 13, 160–166.

Petrovic, P., Pleger, B., Seymour, B., Kloppel, S., De Martino, B., Critchley, H., & Dolan, R. J. (2008). Blocking central opiates function modulates hedonic impact and anterior cingulate response to rewards and losses. *Journal of Neuroscience*, 28, 10509–10516.

Pizzagalli, D. A. (2011). Frontocingulate dysfunction in depression: Toward biomarkers of treatment response. *Neuropsychopharmacology*, 36, 183–206.

Poldrack, R. A., Baker, C. I., Durze, J., Gorgolewski, K. J., Matthews, P. M., Munafò, M. R., … Yarkoni, T. (2017). Scanning the horizon: Towards transparent and reproducible neuroimaging research. *Nature Reviews Neuroscience*, 18, 115–126.

Porchet, R., Bochhoudt, L., Studer, B., Gandamaneni, K., Rani, N., Binnamangala, S., … Clark, L. (2013). Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers. *Frontiers in Behavioral Neuroscience*, 7:138.

Price, D. D., Harkins, S. W., Rafii, A., & Price, C. (1986). A simultaneous comparison of Fentanyl’s analgesic effects on experimental and clinical pain. *Pain*, 24, 197–203.

Price, R. C., Christou, N. V, Backman, B. S., Stone, L., & Schweinhardt, P. (2016). Opioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals. *Psychopharmacology*, 233, 3869–3879.

Primac, D. W., Misky, A. F., & Rosvold, H. E. (1957). Effects of centrally acting drugs on two tests of brain damage. *Archives of Neurology And Psychiatry*, 77, 328–332.

Prossin, A. R., Koch, A. E., Campbell, P. L., Barichello, T., Zaleman, S. S., & Zubieta, J. K. (2015). Acute experimental changes in mood state regulate immune function in relation to central opioid neurotransmission: a model of human CNS-peripheral inflammatory interaction. *Molecular Psychiatry*, 21, 243.

Quednow, B. B., Casmura, P. A., Chmiel, J., Beck, T., & Vollenweider, F. X. (2008). Sensorimotor gating and attentional set-shifting are improved by the μ-opioid receptor agonist morphine in healthy human volunteers. *International Journal of Neuropsychopharmacology*, 11, 655–669.

Rabiner, E. A., Beaver, J., Makwana, A., Searle, G., Long, C., Nathan, P. J., … Bullmore, E. T. (2011). Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. *Molecular Psychiatry*, 16, 826–835.

Redpath, J., & Pleuvry, B. (1982). Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucone phosphate in human volunteers. *British Journal of Clinical Pharmacology*, 14, 555–558.

Ribas-Femandes, J. J. F., Solway, A., Diuk, C., McGuire, J. T., Barto, A. G., Niv, Y., & Botvinick, M. M. (2011). A neural signature of hierarchical reinforcement learning. *Neuron*, 71, 370–379.

Robbins, T. W., & Arnsten, A. F. T. (2009). The neuropsychopharmacology of frontal-executive function: Monoaminergic modulation. *Annual Review of Neuroscience*, 32, 267–287.

Roche, D. J. O., Worley, M. J., Courtney, K. E., Bujarsi, S., London, E. D., Shoptaw, S., & Ray, L. A. (2017). Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. *Psychopharmacology*, 234, 1997–2007.

Rowland, N. E., Mukherjee, M., & Robertson, K. (2001). Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. *Psychopharmacology*, 139, 111–116.

Rukstalis, M., Jepson, C., Strasser, A., Lynch, K. G., Perkins, K., Patterson, F., & Lerman, C. (2005). Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. *Psychopharmacology*, 180, 41–48.

Russell, J. A. (2003). Core affect and the psychological construction of emotion. *Psychological Review*, 110, 145–72.

Saanijoki, T., Tuominen, L., Tuulari, J., Nummenmaa, L., Arponen, E., Kalliokoski, K., & Hirvonen, J. (2018). Opioid release after high-intensity interval training in healthy human subjects. *Neuropsychopharmacology*, 43, 246–254.

Saarialho-Kere, U. (1988). Psychomotor, respiratory and neuroendocrinological effects of nalbuphine and haloperidol, alone and in combination, in healthy subjects. *British Journal of Clinical Pharmacology*, 26, 79–87.

Saarialho-Kere, U., Mattila, M. J., Palohieimo, M., & Seppälä, T. (1987). Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. *European Journal of Clinical Pharmacology*, 33, 139–146.

Saarialho-Kere, U., Mattila, M. J., & Seppälä, T. (1986). Pentazocine and codeine: effects on human performance and mood and interactions with diazepam. *Medical Biology*, 64, 293–299.

Saarialho-Kere, U., Mattila, M. J., & Seppälä, T. (1988). Parenteral pentazocine: Effects on psychomotor skills and respiration, and interactions with amitriptyline. *European Journal of Clinical Pharmacology*, 35, 483–489.

Saarialho-Kere, U., Mattila, M. J., & Seppälä, T. (1989). Psychomotor, respiratory and neuroendocrinological effects of a μ-opioid receptor agonist (oxycodeone) in healthy volunteers. *Pharmacology & Toxicology*, 65, 252–257.

Saunders, B., & Inzlicht, M. (2015). Vigour and fatigue: How variation in affect underlies effective self-control. In T. S. Braver (Ed.), Motivation and cognitive control (pp. 1–46). New York: Taylor & Francis/Routledge.

Schoell, E. D., Bingel, U., Eppert, F., Yacubian, J., Christiansen, K., Andresen, H., … Buechel, C. (2010). The Effect of Opioid
antagonists reduce cue-induced responding and reward impulsivity in humans. *Translational Psychiatry*, 6, e850.

Wechsler, D. (2014). *Wechsler adult intelligence scale–Fourth Edition (WAIS-IV)*. San Antonio, Texas: Psychological Corporation.

Weerts, E. M., McCaul, M. E., Kuwabara, H., Yang, X., Xu, X., Dannals, R. F., …, & Wand, G. S. (2013). Influence of OPRM1 Asn40Asp variant (A118G) on [11C] carfentanil binding potential: Preliminary findings in human subjects. *International Journal of Neuropsychopharmacology*, 16, 47–53.

Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C., & Wager, T. D. (2011). Large-scale automated synthesis of human functional neuroimaging data. *Nature Methods*, 8, 665–670.

Yeomans, M. R. (1995). Opioids and human food choice. *Appetite*, 24, 302.

Yeomans, M. R., & Gray, R. W. (2002). Opioid peptides and the control of human ingestive behaviour. *Neuroscience and Biobehavioral Reviews*, 26, 713–728.

Yik, M. S. M., Russell, J. A., & Barrett, L. F. (1999). Structure of self-reported current affect: Integration and beyond. *Journal of Personality and Social Psychology*, 77, 600–619.

Yovell, Y., Bar, G., Mashiah, M., Baruch, Y., Briskman, I., Asherov, J., …, & Panksepp, J. (2016). Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: A randomized controlled trial. *American Journal of Psychiatry*, 173, 491–498.

Zacny, J. P. (1995). A review of the effects of opioids on psychomotor and cognitive functioning in humans. *Experimental and Clinical Psychopharmacology*, 3, 432–466.

Zacny, J. P. (2003). Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycoxyd) in non-drug-abusing volunteers. *Psychopharmacology, 165*, 146–156.

Zacny, J. P., Coalson, D. W., Lichtor, J. L., Yajnik, S., & Thapar, P. (1994a). Effects of naloxone on the subjective and psychomotor effects of nitrous oxide in humans. *Pharmacology, Biochemistry and Behavior*, 49, 573–578.

Zacny, J. P., Conley, K., & Galinkin, J. (1997a). Comparing the subjective, psychomotor, and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. *Journal of Pharmacology and Experimental Therapeutics*, 282, 1187–1197.

Zacny, J. P., Conley, K., & Marks, S. (1997b). Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Nalbuphine and Morphine in Healthy Volunteers. *The Journal of Pharmacology and Experimental Therapeutics*, 280, 1159–1169.

Zacny, J. P., & de Wit, H. (2009). The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers. *Pharmacology Biochemistry and Behavior*, 94, 108–113.

Zacny, J. P., & Goldman, R. E. (2004). Characterizing the subjective, psychomotor, and physiological effects of oral propoxyphene in non-drug-abusing volunteers. *Drug and Alcohol Dependence*, 73, 133–140.

Zacny, J. P., & Gutierrez, S. (2003). Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. *Psychopharmacology*, 170, 242–254.

Zacny, J. P., & Gutierrez, S. (2008). Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products. *Pain Medicine*, 9, 433–443.

Zacny, J. P., & Gutierrez, S. (2009). Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. *Drug and Alcohol Dependence*, 101, 107–114.

Zacny, J. P., & Gutierrez, S. (2011). Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. *Psychopharmacology*, 218, 471–481.

Zacny, J. P., Hill, J. L., Black, M. L., & Sadeghi, P. (1998). Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. *The Journal of Pharmacology and Experimental Therapeutics*, 286, 1197–207.

Zacny, J. P., Lance Lichtor, J., Binstock, W., Coalson, D. W., Cutter, T., Fleming, D. C., & Glosten, B. (1993). Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers. *Psychopharmacology, 111*, 306–314.

Zacny, J. P., Lichtor, J. L., Fleming, D., Coalson, D. W., & Thompson, W. K. (1994b). A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. *Journal of Pharmacology and Experimental Therapeutics*, 268, 1–9.

Zacny, J. P., Lichtor, J. L., JG, Z., & de Wit, H. (1992). Effects of fasting on responses to intravenous fentanyl in healthy volunteers. *Journal of Substance Abuse*, 4, 197–207.

Zacny, J. P., Lichtor, J. L., Klafu, J. M., Alessi, R., & Apfelbaum, J. L. (1996a). The effects of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers. *Anesthesia and Analgesia*, 82, 931–935.

Zacny, J. P., Lichtor, J. L., Thapar, P., Coalson, D. W., Fleming, D., & Thompson, W. K. (1994c). Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. *Journal of Pharmacology and Experimental Therapeutics*, 270, 579–588.

Zacny, J. P., & Lichtor, S. A. (2008). Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. *Psychopharmacology*, 196, 105–116.

Zacny, J. P., McKay, M. A., Toledano, A. Y., Marks, S., Young, C. J., Klock, P. A., & Apfelbaum, J. L. (1996b). The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. *Drug and Alcohol Dependence*, 42, 133–142.

Zubieta, J.-K. K., Ketter, T. A., Bueller, J. A., Xu, Y. J., Kilbourn, M. R., Weinberger, D. R., & Reprecht, M. J. (1996). Large-scale automated synthesis of human functional neuroimaging data. *Nature Methods*, 8, 665–670.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.